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 20 
Abstract 21 
Vaccines are useful tools to control influenza A virus infection in poultry, but they need to be 22 
periodically reformulated to guarantee appropriate protection from infection and to limit viral 23 
replication and circulation, which could favour the emergence of new variants. In this study, a deep 24 
sequencing approach was used to characterize and follow the evolution of the hemagglutinin of the 25 
H5N1 highly pathogenic avian influenza viral population in infected animals vaccinated with two 26 
vaccines conferring different protection levels. Results from this preliminary investigation 27 
suggested that the evolution of the viral population, as well as the abundance and heterogeneity of 28 
minority variants could be influenced by the immune pressure conferred by vaccination. 29 
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 33 
Introduction 34 
Influenza A virus is a zoonotic agent with a significant impact on both public health and poultry 35 
industry. Vaccination is a useful tool used worldwide to support intervention strategies, such as 36 
stamping out and biosecurity policies, in order to keep the infection under control and prevent the 37 
transmission of avian influenza viruses in poultry (Lee and Suarez, 2005). However, as 38 
demonstrated in previous studies, the use of a vaccine strain antigenically different from the 39 
circulating viruses or application of inadequate vaccine protocols may favour the antigenic drift and 40 
cause vaccination failure (Cattoli et al., 2011b; Lee et al., 2004; Swayne, 2012). A more extensive 41 
knowledge of the mechanisms underlying intra-host evolution of avian influenza viruses circulating 42 
in vaccinated poultry populations could be of help to formulate and adopt more adequate vaccine 43 
strategies. 44 
Previous studies conducted in partially immune pigs indicated that the variability in immune 45 
response may influence the overall diversity of swine influenza virus during infection (Diaz et al., 46 
2015) and showed that the hemagglutinin gene displayed nucleotide mutations at the very beginning 47 
of viral infection (Diaz et al., 2013; Murcia et al., 2012). Still, to date there is no information on the 48 
intra-host evolution of highly pathogenic avian influenza (HPAI) viruses circulating in vaccinated 49 
poultry populations. The hemagglutinin (HA) is a surface glycoprotein, involved in the induction of 50 
a protective humoral and cell mediated immune response, and represents one of the major antigenic 51 
determinants of type A influenza viruses.  52 
To provide some preliminary data on the impact of vaccination on the intra-host diversity and 53 
evolution of HPAI viruses, in this study we performed a deep sequencing analysis of swabs 54 
sampled from H5N1 HPAI experimentally infected chickens, which showed different levels of 55 
clinical and virological protection conferred by two different vaccine formulations.  56 
 57 
Material and methods 58 
A deep sequencing analysis on the HA gene segment was performed on samples collected in a 59 
previously performed vaccination/challenge study for assessing the protective efficacy of two avian 60 
influenza vaccines against a HPAI H5N1 virus. Birds were housed into HEPA filtered poultry 61 
isolators in BSL3 animal facilities and received food and water ad libitum. All animals were 62 
handled in strict accordance with the Decree of the Italian Ministry of Health (n. 26 of 4 March 63 
2014) on the protection of animals used for scientific purposes, implementing Directive 64 
2010/63/EU.  65 
Briefly, two groups of ten Specific Pathogen Free (SPF) day-old chicks were vaccinated twice at a 66 
10-day interval by the sub-cutaneous route, using two distinct influenza inactivated experimental 67 
vaccines. The first vaccination was performed with 0.3 ml and the second vaccination was 68 
performed with 0.5 ml via the subcutaneous route in the back of the neck.  Both vaccines contained 69 
each a recombinant H5-antigen which was encoded by recombinant baculoviruses. Generation of 70 
the recombinant baculoviruses and formulation of the experimental vaccines was performed as 71 
described recently (Oliveira et al, 2016) with one exception, no inactivated antigen of Newcastle 72 
disease virus was added, and 512 HA units were added as H5 antigen. One recombinant baculovirus 73 
encoded for a H5-protein which is included in the VOLVAC® B.E.S.T AI + ND KV (A) belonging 74 
to clade 2.3.2. The second recombinant baculovirus (B) encoded for a consensus sequence (Patent 75 
WO 2012/054907 A2; Sequence ID 43) which was generated based on 37 amino acid sequences of 76 
Egyptian origin viruses from 2010 belonging to either clade 2.2.1 or clade 2.2.1.1.  77 
The birds were challenged with 106 50% Embryo Infectious Dose (EID50) of the HPAI H5N1 78 
A/chicken/Egypt/11VIR4453-7/VRLCU/2010 virus (clade 2.2.1) (WHO/OIE/FAO H5N1 79 
Evolution Working Group, 2012) 21 days after the booster vaccination.  The virus had been isolated 80 
from pooled organs in 9- to 11-day-old SPF embryonated fowls’ eggs. Antibody responses were 81 
assessed by means of hemagglutination inhibition assay (HI), 10 days from the first vaccination, 21 82 
days from the second vaccination and 2 weeks after the challenge. Tracheal swabs (TS) and cloacal 83 
swabs (CS) were collected on days 2, 4, 6, 8 and 10 post challenge (p.c.) to evaluate viral shedding 84 
by quantitative real-time RT-PCR (qRRT-PCR) targeting the M gene (Spackman et al., 2002) and 85 
calculate the EID50 equivalents from the cycle threshold (Ct) values. The Egyptian HPAI H5N1 86 
virus used for the challenge, as well as 20 TS positive by qRRT-PCR, which contain a sufficient 87 
amount of RNA (six samples from group A and fourteen samples from group B), were processed as 88 
described below. Neither of the samples obtained from CS did result in a sufficient signal from the 89 
qRRT-PCR to be included in the analysis. Total RNA was isolated using Nucleospin RNA kit 90 
(Macherey-Nagel, Düren, Germany). Viral RNA encoding the HA gene segment was retro-91 
transcribed and amplified using SuperScript III one-step reverse transcription-PCR (RT-PCR) 92 
system with PlatinumTaq High Fidelity (Invitrogen, Carlsbad, CA) using H5 specific primers (H5-93 
for: 5’-CRAAAGCAGGGGTYCAATC-3’,  H5-rev: 5’-GAAACAAGGGTGTTTTTAAC-3’) . 94 
Sequencing libraries were prepared using Nextera XT DNA Sample preparation kit (Illumina) and 95 
processed as described by Monne et al., 2014 on an Illumina Miseq desktop sequencer. Raw data 96 
were submitted to the NCBI Sequence Read Archive (SRA; 97 
http://www.ncbi.nlm.nih.gov/Traces/sra/) under accession numbers SRR4244068, SRR4244069, 98 
SRR4244070, SRR4244071, SRR4244072, SRR4244073, SRR4244074, SRR4244076, 99 
SRR4244077, SRR4244078, SRR4244079, SRR4244080, SRR4244081, SRR4244082, 100 
SRR4244083, SRR4244084, SRR4244085, SRR4244086, SRR4244087, SRR4244088, 101 
SRR4244089. 102 
FASTQC software was used to inspect quality score of raw sequence files and post processing data 103 
coming from the high-throughput sequencing pipelines. Fastq files were cleaned with Trimmomatic 104 
v0.32 (Bolger et al., 2014), using a 4-base-pair sliding-window algorithm with a quality score cut-105 
off of 20; only reads longer than 80 nucleotides were considered and mapped to the hemagglutinin 106 
H5 reference sequence A/chicken/Egypt/11VIR4453-7/VRLCU/2010 (Gisaid accession number 107 
EPI348162) using bwa v0.7.5 (Li and Durbin, 2010). The alignment was processed with LoFreq 108 
v2.1.2 (Wilm et al., 2012) for the SNP calling; according to LoFreq usage recommendations, the 109 
alignment was first processed with Picard-tools v2.1.0 (http://broadinstitute.github.io/picard/) and 110 
GATK v3.5 (DePristo et al., 2011; McKenna et al., 2010; Van der Auwera et al., 2013). The 111 
frequencies of variants in the final set were computed using the diversiTools program v0.1.19 112 
(http://josephhughes.github.io/btctools/) and confirmed by those found with LoFreq. Variants with 113 
sequence coverage less than 500X or frequency less than 1% were discarded. The numbering 114 
scheme of the amino acid residues used in this study is based on the mature sequence (signal 115 
peptide was cleaved off) of the HA of A/Vietnam/1203/2004 (H5N1) (GenBank accession number 116 
HM006759).  117 
To explore the amino acid variability at the resulted polymorphic sites in the Egyptian H5N1 viral 118 
population, the full-length hemagglutinin sequences of H5N1 Egyptian viruses (from 2006 to 2016) 119 
were downloaded from the public database (GenBank) collapsing identical ones; a total of 345 120 
protein sequences was obtained. The sequences were then aligned using the on-line MAFFT 121 
program (http://mafft.cbrc.jp/alignment/server/) and amino acid composition at the selected 122 
positions was carefully inspected. 123 
From our NGS data we then calculated the Shannon Entropy (SE). SE is a measure of diversity 124 
within a viral population at a single nucleotide position or a whole sequence level. In a specific site, 125 
the highest value of SE is reached when the four nucleotides are present at a frequency of 25%, 126 
while the lowest value (zero) is obtained when only one nucleotide is present at a frequency of 127 
100%. Low entropy may be observed in case of a significant reduction of the population size, i.e., 128 
following a bottleneck event, which at a single nucleotide level results in low or no variability. In 129 
our study Shannon Entropy was used to quantify average diversity of the HA gene of the viral 130 
populations of each sample belonging to group A and B, using the following formula: 131 
𝐸 =  −
1
𝑁
∑ (𝑓𝑖𝐴
𝑁
𝑖=1
ln 𝑓𝑖𝐴 + 𝑓𝑖𝐺 ln 𝑓𝑖𝐺 + 𝑓𝑖𝑇 ln 𝑓𝑖𝑇 + 𝑓𝑖𝐶 ln 𝑓𝑖𝐶)  132 
where 𝑓𝑖 is the frequency of the nucleotide A, C, G or T at position i and N is the total length of the 133 
hemagglutinin gene. 134 
The Wilcoxon Mann–Whitney rank-sum test was used to verify whether the distribution of EID50 135 
and Entropy values was the same in both vaccine groups; only six samples were collected at 4 days 136 
p.c., five from group B and one from group A, therefore they were excluded from the statistical 137 
comparison. The same test was used to assess whether the distributions of Entropy were identical 138 
between the challenge virus and each sample of groups A and B. P-value < 0.10 was considered 139 
significant. The Pearson product-moment correlation coefficient was used to verify whether the 140 
population diversity (represented by SE) and the quantity of virus (represented by EID50) were 141 
independent so as to exclude that differences of SE between group A and B were due to EID50 142 
values. 143 
 144 
Results 145 
To provide some preliminary data on the impact of vaccination on the intra-host diversity and 146 
evolution of HPAI viruses, in this study we performed a deep sequencing analysis of swabs 147 
sampled from SPF chickens immunized with two different vaccines that,  upon H5N1 HPAI 148 
challenge exhibited different levels of clinical and virological protection, expressed as reduction of 149 
mortality and shedding, respectively. All of the birds that received vaccine A survived the challenge 150 
(100% protection from mortality) and only 2/10 birds showed moderate depression that in one 151 
animal was coupled with nervous signs. Vaccine B prevented mortality in 70% of the birds (Tab. 1) 152 
and all of the surviving animals showed moderate signs of inactivity and depression. Moreover, the 153 
vaccines differed in terms of suppression of viral shedding, as at each time p.c. fewer birds in group 154 
A had shed viral RNA from the trachea (Tab. 1), and the amount of virus shed was significantly 155 
lower than in group B on day 2 p.c. (p=0.072) (Fig. 1). Ten days after the first vaccination, animals 156 
in both groups showed no detectable levels of HI antibodies against the challenge virus. After the 157 
booster vaccination, birds in group A recorded a 2.6 log2 HI geometric mean titre (GMT) against 158 
the challenge virus, whereas in group B all birds resulted either negative or recorded HI titres of 1 159 
log2 (GMT of 0.2 log2). After the challenge, seroconversion, expressed as an HI GMT increase 160 
equal to or higher than 2 log2, was observed in all of the surviving birds in group B (GMT of 2.2 161 
log2), as opposed to 50% of the animals in group A (HI GMT of 3.0 log2). 162 
A sufficient amount of amplification product (>0.2 ng/μl) for deep sequencing analysis was 163 
recovered from TS only on days 2 and 4 p.c.. Data were obtained for a total of twenty-one positive 164 
samples, specifically: a) the challenge virus ,  b) six samples belonging to group A, five of which at 165 
day 2 p.c. (34A2, 35A2, 37A2, 47A2, 59A2) and one at day 4  p.c. (34A4), and c) fourteen samples 166 
belonging to group B, nine of which at day 2  p.c. (72B2, 73B2, 75B2, 79B2, 80B2, 81B2, 83B2, 167 
86B2, 88B2) and five at day 4  p.c. (73B4, 79B4, 81B4, 86B4, 88B4). Each sample was identified 168 
as follows: the first two digits refer to the animal identification code, the alphabetic character (A or 169 
B) identifies the group and the last digit indicates the number of days p.c. 170 
To characterize the complexity of the viral population of the 20 swab samples from the vaccinated 171 
birds, the per-site Shannon Entropy was calculated, considering the frequencies of nucleotide 172 
substitutions across the hemagglutinin gene. The Entropy measures fluctuated considerably: the 173 
samples with the lowest values belonged to group A (0 and 2.3 x 10-4), while the ones with the 174 
highest values (7.2 x 10-4 and 7.7 x 10-4) belonged to group B. 175 
The non-parametric Wilcoxon Mann–Whitney test indicated that the distribution of Entropy values 176 
were different in the two vaccination groups (p=0.0041), with group B showing the highest values 177 
(fig 1). Compared to the challenge virus, four out of five samples of group A collected at day 2  p.c. 178 
showed significantly different Entropy values (p-values range from 0.0142 to 0.0587). These four 179 
samples had a lower Entropy value than the one of the challenge virus (data not shown). All 180 
samples belonging to group B recorded Entropy values without significant differences compared to 181 
the Entropy of the challenge virus. Pearson test between the within-host virus diversity and the viral 182 
shedding (EID50) showed no significant correlation between Entropy and EID50 values (r=0.23 with 183 
p-value=0.4297), suggesting that the different Entropy values observed in the viruses of group A 184 
may have been  due to the occurrence of bottleneck events as a consequence of the vaccine selective 185 
pressure. 186 
The analysis of the nucleotide sequence diversity of the hemagglutinin gene showed several 187 
synonymous and non-synonymous polymorphisms distributed on the HA gene of almost all 188 
samples. However, a comparison between the two groups revealed a great variability in the number 189 
of polymorphisms among samples. Specifically, the six samples belonging to group A showed from 190 
zero to four minority variants per sample (tab. 2), randomly distributed across nine nucleotide 191 
positions, with a frequency ranging from 1.12% to 6.88%. None of the identified polymorphic sites 192 
were shared among samples. On the other hand, group B displayed a higher number of 193 
polymorphisms (tab. 3), from two to thirteen per sample, distributed in fifty-seven positions and 194 
showing a frequency ranging from 1.02% to 68.70%. Interestingly, three of these polymorphisms 195 
(residues 258, 470 and 1379) were independently acquired by two or more samples of group B, 196 
while none of the minority variants was shared between group A and B. 197 
In addition, we found that most of the identified mutations had been newly acquired during the viral 198 
replication in host. Indeed, only three minority variants identified at the nucleotide positions 164, 199 
1032 and 1395 of the HA gene of seven group B samples were already present in the challenge 200 
strain material, while none of the polymorphisms observed in the challenge virus material were later 201 
identified among samples belonging to group A, thus suggesting an even narrower bottleneck. 202 
Non-synonymous substitutions represented 67% of the total polymorphisms both in group A and B 203 
and were randomly distributed across the HA gene. Among samples belonging to group A, six 204 
nucleotide positions, across the whole HA gene, showed non-synonymous minority variants with a 205 
frequency ranging from 1.12% to 6.88%. None of them were located at the globular head of the 206 
HA1 protein near or within the three secondary structural elements of the receptor binding domain 207 
(RBD) (Kovácová et al., 2002), formed by the 130-loop, 190-helix, and 220-loop, and/or in 208 
previously identified antigenic sites (Kaverin et al., 2007, 2002). On the other hand, group B 209 
showed a higher number of nucleotide positions (forty-two) displaying non-synonymous mutations 210 
with a frequency ranging from 1.02% to 38.84% (tab. 3). Interestingly, we identified two non-211 
synonymous SNPs at positions 1018 and 1019 responsible of the mutations R325K and R325G 212 
situated at the HA cleavage site for two samples, collected respectively at 2 and 4 days p.c. In 213 
addition, ten of the polymorphisms acquired by six out of nine samples at 2 days p.c. and by one out 214 
of five samples at 4 days p.c. fell within the receptor binding cavity of the HA. In particular, C135F 215 
and S142Y/F were positioned respectively within and close to the 130 loop, whereas K218E was 216 
located within the 220 loop. Moreover, five of these minority variants fell close to or within 217 
antigenic sites previously characterized in the H5 strains: site 1 (S1) and site 2 (S2) (Kaverin et al., 218 
2007, 2002).  In particular, three non-synonymous SNPs (C135F, S142Y and S142F), found in one 219 
sample at 2 days p.c. and in one sample at 4 days p.c., flanked the site 1 (136-141), which 220 
corresponds to antigenic site A in H3 and Ca2 of H1, while the two minority variants T151I and 221 
Y157C, detected in sample 79B2 and 80B2, were respectively located within and close to site 2 222 
(residues 151-156), which corresponds to antigenic site B in H3. Considering the distinct results 223 
obtained from the two experimental groups, the percentage of amino acid identity between the two 224 
vaccines and the challenge virus was calculated. The sequence of the HA protein (except for the 225 
signal peptide) of the challenge virus showed a percentage of amino acid identity with vaccine A 226 
and B of 96.4% and 95.3%, respectively. Moreover, the identity of the sequence coding for the HA 227 
receptor binding pocket (from amino acid 130 to 225, H5 numbering) of the challenge virus with 228 
vaccine A and B corresponded to 93.6% and 85.1%, respectively. These findings may suggest that 229 
the suboptimal protection conferred by vaccine B seems to have favoured the occurrence of a higher 230 
number of molecular changes in the challenge virus. 231 
Two samples belonging to group B (73B2 and 79B4) displayed stop codons at amino acid positions 232 
122 in sample 73B2 and 149 and 518 in sample 79B4. This observation could suggest the formation 233 
of defective virus particles as previously shown (Hoelzer et al., 2010; Murcia et al., 2012). 234 
To explore whether the amino acid polymorphisms identified in this study had emerged also in field 235 
strains circulating under vaccination pressure, we analysed all the non-redundant hemagglutinin 236 
sequences of H5N1 viruses available in GenBank that had been collected in Egypt between 2006 237 
and 2016. We found at least one sequence displaying the same mutation identified in our samples at 238 
the amino acid positions 121, 151, 312, 324, 325, 369, 373, 393 and 528. Positions 151 and 325 239 
showed the highest variability; in particular, amino acid position 151 showed 51% T and 62% I, 240 
whereas position 325 showed 52% R, 29% K and 12% G. Furthermore position 324 showed 97.3% 241 
E and 2.3% K, whereas position 373 showed 96.5% K, and 3.5% R.  242 
 243 
Discussion  244 
For many influenza subtypes, such as HPAI H5N1 virus, vaccination programmes are currently 245 
implemented in a number of countries with the goal to control this disease in poultry populations 246 
(Swayne, 2012).  However, influenza A viruses evolve rapidly in response to selection pressures 247 
generated through vaccine protection (Cattoli et al., 2011a), and the emergence of virus strains, for 248 
which existing vaccines are not well matched and offer little protection, continuously challenges the 249 
effectiveness of vaccines in the field (Connie Leung et al., 2013; Kim et al., 2010). To better 250 
understand the dynamics of the emergence of antigenic drifted variants, we performed a deep 251 
sequencing analysis of 20 samples collected in the framework of a previous experimental study 252 
conducted in our institute to assess the protection efficacy of two distinct vaccines against a HPAI 253 
H5N1 virus. In particular, the two experimental challenge groups (A and B) allowed to mimic 254 
different level of immunity and to explore how viruses evolve within hosts that have developed 255 
suboptimal immunity with influenza vaccines. All of the birds that had received vaccine A survived 256 
the challenge, whereas vaccine B prevented mortality in 70% of the birds. The results obtained 257 
applying a deep sequencing approach to samples collected from the groups A and B and to the 258 
challenge virus suggests that a suboptimal level of antibody protection may favour the increase of 259 
viral population heterogeneity from the early stages of infection and may promote the selection of 260 
minority variants, some of which may be involved in antigenic drift.  261 
We identified a total of 9 minority variants (frequency range from 1.12% to 6.88%) in group A and 262 
64 minority variants (frequency range from 1.05% to 38.84%) and 2 fixed mutations (frequencies 263 
54.44% and 68.70%) in group B. Although no marked differences were highlighted between the 264 
two groups in the ratio of synonymous to non-synonymous substitutions (67% of SNP identified in 265 
both groups were non-synonymous), evidence of non-synonymous mutations in the RBD or in the 266 
antigenic sites (S1 and S2) were found only in group B. However, whether these non-synonymous 267 
polymorphisms had emerged by chance or as a consequence of strong selection could not be 268 
assessed. None of the samples taken at day 4 p.c. showed a fixation of non-synonymous 269 
substitutions indicating they may be transient, or else there may have been insufficient time for the 270 
minority variant to become fixed in the viral population, since mutations that alter HA antigenicity 271 
may engender a cost in the viral fitness, which requires compensatory mutations to restore viral 272 
replicative ability. Interestingly, mutation T151I located in the RBD and antigenic site 2 is present 273 
in 62% of the Egyptian H5N1 sequences available in GenBank, meaning that this mutation may be 274 
naturally selected during circulation of H5N1 viruses in the field. In addition, two samples 275 
belonging to group B displayed minority variants R325K and R325G situated within the cleavage 276 
site of the hemagglutinin protein. A previous study carried out on Egyptian HPAI H5N1 viruses 277 
showed that the amino acid glycine at position 325 had significantly reduced pathogenicity without 278 
altering the transmission efficiency (Yoon et al., 2013). Both mutations were observed in the H5N1 279 
viruses collected from poultry in Egypt. Specifically, R325K was observed in the recent viruses 280 
from clade 2.2.1.2, while R325G characterized the Egyptian clade 2.2.1.1a (Arafa et al., 2016). 281 
Considering that our sample size was rather limited and that no samples from non-vaccinated 282 
control birds were suitable for sequencing, and since all of the animals had died soon after the HPAI 283 
H5N1 infection, this study should be further confirmed by making an assessment on a greater 284 
number of samples collected over a wider range of time. In addition, further studies on the whole 285 
influenza A virus genome could provide an overview on the effect of vaccine immune pressure on 286 
the evolution of the viral genome and, consequently, on viral proteins. However, the identification 287 
of some of the minority variants in field viruses circulating in a partially immune population may 288 
indicate that in natural conditions these mutations can arise and be selected, providing a fitness 289 
advantage to the viruses. 290 
To our knowledge, this is the first time that we are provided with evidence showing that infection of 291 
properly vaccinated birds is dominated by narrow genetic bottlenecks, resulting in a reduction of 292 
genetic variation. On the other hand, the infection of partially immune poultry appears to allow the 293 
virus to increase its genetic heterogeneity and to accumulate mutations that may alter HA 294 
antigenicity. Furthermore, vaccine A seems to have played a bottleneck effect as four out of five 295 
animals at day 2 p.c. had showed significantly lower Entropy values compared to the challenge 296 
virus. Overall our findings are in accordance with the results obtained in infected and vaccinated 297 
pigs (Diaz et al., 2015), where the authors suggested that the viral population diversity and 298 
evolution might be influenced by the level of immune response to influenza A virus vaccine. 299 
Results from this study provide proof of concept data that pave the way for further investigations on 300 
the effect of vaccine immune pressure on the generation of genetic diversity at the subpopulation 301 
level. 302 
 303 
Conclusion 304 
Deep sequencing analysis proved to be a valid tool to explore and characterize differences among 305 
viral populations in vaccinated animals during infection. This technique detected the presence of 306 
minority variants that could not have been revealed by a classical sequencing method. This work 307 
highlights the potential value of the NGS approach for the assessment of vaccine efficacy and as a 308 
suitable method to understand the mechanisms that underpin how viruses escape vaccine protection. 309 
The deep sequencing analysis of samples collected from vaccine challenge studies early during the 310 
infection might serve as a predictive tool to infer virus population heterogeneity and hence 311 
effectiveness of vaccine control programmes. 312 
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 417 
Figure legend 418 
Figure 1. Box plots of EID50 and Entropy by vaccination group. The boxplots display the distribution of the 419 
quantitative values of EID50 (left) and Entropy (right) for samples collected at 2 days p.c. of each 420 
vaccination group. The y-axis represents the EID and Entropy values. Each box shows the degree of 421 
dispersion in the data. The line inside the box is the median value; the points above the box are the outliers. 422 
 423 
Table 1. Number of positive swabs (viral shedding) and survival rates of groups A and B. 
 
 Number of positive swabs Survival 
rate 
% 
Days p.c. 2  4  6  8  10  
 TSb CSc TS CS TS CS TS CS TS CS 
Vaccine A a 8/10d 0/10 5/10 0/10 1/10 0/10 0/10 0/10 0/10 1/10 100 
Vaccine B a 10/10 0/10 8/10 1/10 2/8 1/8 1/8 2/8 1/7 0/7 70 
Control NA e NA NA NA NA NA NA NA NA NA 0 
a Vaccine A (B.E.S.T AI ) and B (Consensus) were used for  a two-fold vaccination at day 1 and 10 post hatch 
b Tracheal swab 
c Cloacal swab 
d Number of chickens positive in qRRT-PCR/total number of chickens 
e Not applicable since all birds of the control group died on day 1 post challenge infection 
 
Table 2. SNPs identified in samples belonging to group A and virus of challenge; frequency values 
are in percentage. SIL: silent mutation, CDS: coding sequence, POLYM: polymorphism at aa 
position (signal peptide is not included in the numbering).  
 
 
CDS POLYM Chall 34A2 35A2 37A2 47A2 59A2 34A4 
164 G39E 5.06       
229 L61F  1.34      
238 N64D  1.54      
489 SIL       1.13 
849 SIL 1.26       
1032 SIL 1.64       
1190 V382A    1.12    
1222 F393L     6.88   
1236 SIL       2.01 
1290 SIL 1.64       
1395 SIL 1.07       
1400 V452A       2.72 
1615 SIL 2.32       
1625 L527P       2.35 
1701 SIL   1.37     
 
 
 
Table 3. SNPs identified in samples belonging to group B and virus of challenge; frequency values 1 
are in percentage. S1: antigenic site S1; S2: antigenic site S2; 130L: 130 loop; 220L: 220 loop. The 2 
box represents the residues included in the Receptor Binding Domain; SIL: silent mutation, CDS: 3 
coding sequence, POLYM: polymorphism at amino acid position (signal peptide is not included in 4 
the numbering). 5 
CDS POLYM Site Chall 72B2 73B2 75B2 79B2 80B2 81B2 83B2 86B2 88B2 73B4 79B4 81B4 86B4 88B4 
149 E34G            7.93     
153 SIL                2.86 
160 N38D        1.52         
164 G39E  5.06       38.84        
213 SIL            1.59     
258 SIL    2.38       16.68     32.74 
268 SIL                2.72 
357 H103Q    2.30             
410 S121F               3.49  
411 SIL    1.44             
414 W122*    1.49             
449 C135F S1 130L   2.28             
458 SIL   1.25              
470 S142Y/F S1   1.65           3.88  
492 W149*             1.75    
497 T151I S2     4.46           
515 Y157C S2      3.00          
536 Y164C          5.35       
555 E170D        5.29         
585 SIL               2.89  
682 I213V           1.50      
686 A214D      3.77           
697 K218E 220L              1.05  
804 SIL              1.74   
828 SIL       1.39          
848 E268G         3.56        
849 SIL  1.26               
880 Q279K          3.92       
931 P296S      5.16           
979 V312I    1.30             
985 A314T             1.98    
1015 E324K         2.66        
1018 R325G              1.44   
1019 R325K    1.33             
1032 SIL  1.64  1.58 68.70  54.44     6.74 1.25   15.16 
1048 A335T    1.27             
1071 SIL         1.66        
1107 SIL             1.20    
1119 N358D    1.40             
1150 E369K      10.51           
1163 K373R             1.02    
1199 I385T          2.26       
1264 I407L             1.29    
1290 SIL /E415D  1.64  1.42             
1327 L428F    2.13             
1349 E435G     2.92            
1364 F440S              2.71   
1365 SIL             1.84    
1379 V445A      5.67  1.54         
1394 D450G         3.96        
1395 SIL  1.07          6.62     
1429 E462K             1.61    
1504 Y487H        1.22         
1517 Q491L      2.50           
1522 S493P   2.53              
1575 SIL               2.67  
1598 S518*             1.05    
1615 SIL  2.32               
1628 A528V           1.25      

